Beta-lactam and Beta-lactamase Inhibitors Market Research Report 2020 Observational Studies with Top Manufacturers like Novartis International AG


Posted January 24, 2021 by sheshk234

At an estimated value of over 27.49 billion USD in 2019, the global Beta-lactam and Beta-lactamase Inhibitors Market is predicted to thrive at a CAGR of 1.9% and valued at over USD 34.20 billion over the forecast year 2020-2030.

 
At an estimated value of over 27.49 billion USD in 2019, the global Beta-lactam and Beta-lactamase Inhibitors Market is predicted to thrive at a CAGR of 1.9% and valued at over USD 34.20 billion over the forecast year 2020-2030.

Beta-lactam inhibitors fall under a class of antibiotics that consists of all antibiotic agents that have a beta lactam ring embedded in their molecular structure. These antibiotic agents helps fight against bacterial infections and protozoa infections. The antibiotic agent either completely kills the bacteria or prevents it from growing and expanding. Names of some beta-lactam antibiotics are penicillin, cephalosporin and many others. On the other hand, beta-lactamase inhibitors are a class of drugs that block the activity of beta-lactamase enzymes and restricts the degradation of beta-lactam. Beta-lactamase enzymes are created either constitutively or on exposure to antimicrobials.

Access Full Description of this report at:-

https://www.nextmsc.com/report/beta-lactam-beta-lactamase-inhibitors-market

Top Companies: Abbott Laboratories, Allergan plc. F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Merck & Co. Inc. Mylan N.V., Novartis International AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries and others.

The global beta-lactam and beta-lactamase inhibitors market share has been segmented on the basis of drug class, disease, route of administration and geography. On the basis of drug class, the market is categorized into Penicillin, Cephalosporin, Carbapanem, Monobactam and combination. Combination is sub segmented into Penicillin/Beta Lactamase inhibitors, Cephalosprin/Beta Lactamase inhibitors and Carbapanem/Beta inhibitors. On the basis of disease, the market is segmented into Urinary Tract Infection (excluding cUTI), Respiratory Infection, Skin Infection, Complicated Urinary Tract Infection (cUTI), Complicated Intra-Abdominal Infections (cIAI), Nosocomial Pneumonia, Blood Stream Infection and others. Nosocomial Pneumonia is sub segmented into Hospital Acquired Pneumonia, Ventilator Associated Pneumonia and other. Based on route of administration, the market is segmented into oral, intravenous and others. In terms of geography, the market is categorized into North America, Europe, Asia Pacific and RoW.

Request sample copy of this report at:-

https://www.nextmsc.com/beta-lactam-beta-lactamase-inhibitors-market/request-sample

The North America region is anticipated to hold the major market share as a result of advanced health care facilities and infrastructure in conjunction with rise in acceptance of beta-lactam and beta-lactamase inhibitors. The Asia Pacific region is predicted to show rapid and consistent growth in market share within the forecast period. This region also indicates increased prevalence of infectious diseases in addition to rise in consumption of such drugs, which also serves as favorable factor for the beta-lactam and beta-lactamase inhibitor market.

About Next Move Strategy Consulting:

Next Move Strategy Consulting is an independent and trusted third-platform market intelligence provider, committed to deliver high quality, market research reports that help multinational companies to triumph over their competitions and increase industry footprint by capturing greater market share. Our research model is a unique collaboration of primary research, secondary research, data mining and data analytics.

We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicate as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solution that ranges from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.

For more insights, please visit, https://www.nextmsc.com
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Shesh
Country India
Categories Health
Tags betalactam and betalactamase inhibitors market
Last Updated January 24, 2021